Literature DB >> 8639842

Engagement of the adhesion receptor CD22 triggers a potent stimulatory signal for B cells and blocking CD22/CD22L interactions impairs T-cell proliferation.

J Tuscano1, P Engel, T F Tedder, J H Kehrl.   

Abstract

The B-lymphocyte-restricted adhesion protein CD22 mediates sialic acid-dependent cell-cell interactions. Engagement of CD22 on B lymphocytes with a CD22 monoclonal antibody (MoAb) HB22.7 that blocks the binding of CD22 to its ligand(s) directly stimulated B-cell proliferation. In addition, the HB22.7 MoAb costimulated B-cell proliferation with either anti-IgM, interleukin-2 (IL-2), IL-4, or CD40 and triggered predominantly B-cell IgG secretion with IL-2. Even more striking levels of B-cell proliferation occurred with HB22.7 MoAb under culture conditions that enhanced B-B-cell interactions. In contrast, a nonblocking CD22 MoAb (CD22.5) poorly costimulated in similar experiments. The functional differences between the two antibodies likely result from differing abilities to trigger downstream signaling events as significant differences in CD22 tyrosine phosphorylation and the recruitment of the tyrosine kinase p53/56lyn and the tyrosine phosphatase SH-PTP1C were found. Besides their role in B-cell stimulation, CD22/CD22L interactions may also assist in regulating T-cell proliferation because inhibition of CD22-CD22L engagement with the HB22.7 MoAb impaired T-cell proliferation in a costimulatory assay. Thus, CD22/CD22L interactions result in stimulatory signals for both B and T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8639842

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1.

Authors:  J J Perez-Villar; G S Whitney; M A Bowen; D H Hewgill; A A Aruffo; S B Kanner
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

2.  CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells.

Authors:  Mary K O'Reilly; Hua Tian; James C Paulson
Journal:  J Immunol       Date:  2010-12-22       Impact factor: 5.422

3.  In situ trans ligands of CD22 identified by glycan-protein photocross-linking-enabled proteomics.

Authors:  T N C Ramya; Eranthie Weerapana; Lujian Liao; Ying Zeng; Hiroaki Tateno; Liang Liao; John R Yates; Benjamin F Cravatt; James C Paulson
Journal:  Mol Cell Proteomics       Date:  2010-02-19       Impact factor: 5.911

Review 4.  The sialyl-alpha2,6-lactosaminyl-structure: biosynthesis and functional role.

Authors:  F Dall'Olio
Journal:  Glycoconj J       Date:  2000-10       Impact factor: 2.916

5.  The effect of alpha2,6-linked sialic acid on anti-IgM antibody-induced apoptosis in Ramos cells.

Authors:  Y Azuma; M Sakanashi; K Matsumoto
Journal:  Glycoconj J       Date:  2001-05       Impact factor: 2.916

Review 6.  Viewing Siglecs through the lens of tumor immunology.

Authors:  Isabella Fraschilla; Shiv Pillai
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

7.  Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact.

Authors:  Brian E Collins; Ola Blixt; Alexis R DeSieno; Nicolai Bovin; Jamey D Marth; James C Paulson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

Review 8.  CD22: an inhibitory enigma.

Authors:  Jennifer A Walker; Kenneth G C Smith
Journal:  Immunology       Date:  2007-12-07       Impact factor: 7.397

9.  Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts.

Authors:  Robert T O'Donnell; Yunpeng Ma; Hayes C McKnight; David Pearson; Joseph M Tuscano
Journal:  Cancer Immunol Immunother       Date:  2009-05-13       Impact factor: 6.968

10.  Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD).

Authors:  Robert T O'Donnell; Shiloh M Martin; Yunpeng Ma; William C Zamboni; Joseph M Tuscano
Journal:  Invest New Drugs       Date:  2009-03-24       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.